Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777491 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00777491 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 70 participants.
The verdict
NCT00777491, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different chemotherapy and radiation therapy regimens to see how they work in treating patients with stage II or stage III bladder cancer that was removed by surgery.
Interventions
- DRUG induction cisplatin
- DRUG induction 5-fluorouracil
- DRUG induction gemcitabine
- RADIATION Induction BID radiation therapy
- RADIATION Induction QD radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-12 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00777491
The ClinicalTrials.gov registry entry for NCT00777491 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which induction cisplatin is the first listed.
NCT00777491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00777491 about?
NCT00777491 is a clinical study titled "Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery". RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy togethe...
What is the current status of trial NCT00777491?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2008-12. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00777491?
The interventions under investigation include: induction cisplatin (DRUG), induction 5-fluorouracil (DRUG), induction gemcitabine (DRUG), Induction BID radiation therapy (RADIATION), Induction QD radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00777491?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.